Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioequivalence of Tavapadon Tablets in Parkinson's Disease
NCT05610189Phase 1Completed
- Sponsor
- Cerevel Therapeutics
- Start
- Dec 2022
- Primary completion
- Dec 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of tavapadon in Parkinson's disease (PD) (2 cohorts), sponsored by Cerevel Therapeutics. Primary endpoints: Maximum Observed Plasma Concentration and Area Under the Plasma Concentration-time Curve Over the Dosing Interval. Started Dec 2022; status: completed.
02
Drugs
tavapadon
03
Conditions
Parkinson's disease (PD)
Beyond the preview
Go deeper on NCT05610189.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05610189.